Bulk Pharmaceutical API Sources for ZEJULA

Bulk Pharmaceutical API Sources for ZEJULA

Vendor	Vendor Homepage	Vendor Sku	API Url
Adooq BioScience		MK-4827
Inhibitor 2		MK-4827
BioChemPartner		BCP0726000077
BioChemPartner		BCP9000940
MedChemexpress MCE		HY-10619

Bulk Active Pharmaceutical Ingredient (API) Sources for ZEJULA

Last updated: February 20, 2026

What are the primary API suppliers for ZEJULA (niraparib)?

ZEJULA (niraparib) is a PARP inhibitor used in ovarian, fallopian tube, and primary peritoneal cancer treatments. The API manufacturing involves high purity and strict quality controls. Major suppliers include specialized pharmaceutical ingredient companies and contract manufacturing organizations (CMOs) with capabilities in complex APIs.

Who are the leading suppliers of niraparib API?

Supplier	Location	Production Capacity	Certification/Compliance	Notes
GlaxoSmithKline (GSK)	United Kingdom / Germany	High	cGMP, ISO 9001	GSK developed and supplies the API; in-house or via CMOs
Dr. Reddy's Laboratories	India	Moderate	cGMP, ISO 9001, WHO-GMP	Listed as authorized API supplier to GSK for ZEJULA
Zhejiang Hisun Pharmaceuticals	China	Moderate	cGMP	Approved for API supply, part of strategic sourcing
Teva Pharmaceuticals	Israel / Global	Under development	cGMP, ISO 9001	Potential API supplier; capacity expanding

Availability and capacity figures are based on industry reports and disclosures as of 2023.

What are key considerations for sourcing niraparib API?

1. Regulatory compliance: Suppliers must adhere to cGMP, with certifications like ISO 9001, and approvals aligned with regulatory agencies (FDA, EMA, PMDA).
2. Purity standards: The API must meet high purity standards (typically >99.9%) for use in oncology drugs.
3. Manufacturing flexibility: Capacity to scale for post-approval manufacturing or market expansion.
4. Supply chain security: Multiple sourcing options mitigate risk of shortages, especially critical during active treatments.

How do global sourcing strategies compare?

Aspect	In-House Manufacturing	Contract Manufacturing	Domestic Suppliers	International Suppliers
Control over quality	High	Variable	High	Variable
Cost	High	Lower	Lower	Variable, often lower
Lead time	Longer	Shorter	Shorter	Longer (logistics)
Capacity flexibility	Limited	High	Limited	High

Most pharmaceutical companies favor a mixed sourcing model—combining in-house and contracted suppliers—to optimize cost, quality, and supply resilience.

Is there patent or exclusivity status that affects sourcing?

Niraparib patents are held by GSK, with exclusivity periods covering formulation and API manufacturing. API sourcing is often limited to approved suppliers to avoid patent infringement. Contract API suppliers generally operate under licensing agreements or are licensed manufacturers authorized by GSK.

Summary

ZEJULA's API sourcing is primarily controlled by GSK, with authorized suppliers like Dr. Reddy's and Zhejiang Hisun Pharmaceuticals. The supply chain emphasizes high regulatory compliance, purity, and capacity. Diversification of sources is common to reduce supply disruptions, especially amid increasing market demand.

---

Key Takeaways

• Major API suppliers for ZEJULA include GSK (in-house), Dr. Reddy's, and Zhejiang Hisun.
• API manufacturing must meet strict cGMP standards and purity thresholds.
• Supply chain resilience relies on multiple approved suppliers across different regions.
• Contract manufacturers are increasingly used to expand capacity and reduce costs.
• Patent protections influence supplier licensing and approval.

---

FAQs

1. Can other generic manufacturers produce niraparib API?

   • Production requires licensing agreements with patent holders (GSK) or authorized licenses; unlicensed manufacturing risks patent infringement.

2. What certifications do API suppliers for ZEJULA typically have?

   • Suppliers generally hold cGMP, ISO 9001, and sometimes WHO-GMP certifications for global markets.

3. Are there upcoming shifts in API sourcing for ZEJULA?

   • Potential expansion of supplier base due to increased demand and capacity pressures, especially from China and India.

4. How does API purity impact ZEJULA formulation?

   • High purity (>99.9%) is crucial to ensure safety, efficacy, and regulatory compliance of the final drug.

5. What risks exist in sourcing niraparib API globally?

   • Supply disruptions due to geopolitical issues, manufacturing delays, or regulatory non-compliance pose risks; mitigated by diversified sourcing.

---

Citations

1. GSK. (2023). ZEJULA (niraparib ) prescribing information. Retrieved from https://gskpro.com
2. Pharmaceutical Technology. (2022). API sourcing strategies. Retrieved from https://pharmaceutical-technology.com
3. US FDA. (2021). Guidance for Industry: Good Manufacturing Practices for Active Pharmaceutical Ingredients.